High expression of topoisomerase-II predicts favorable clinical outcomes in patients with relapsed small cell lung cancers receiving amrubicin

Yosuke Miura,Kyoichi Kaira,Reiko Sakurai,Noriaki Sunaga,Ryusei Saito,Takeshi Hisada,Masanobu Yamada

Lung Cancer（2018）

引用 9|浏览17

暂无评分

摘要

•We examined clinical outcomes in relapsed SCLC patients who received amrubicin.•Higher Topo-II expression correlated closely with refractory relapse in patients.•Topo-II overexpression was an independent prognostic factor for better outcomes.•Topo-II expression may be a potent indicator of the efficacy of amrubicin therapy.

查看译文

关键词

Small cell lung cancer,Topoisomerase-II,Amrubicin,Prognostic factor,Immunohistochemistry

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要